The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

Disclosed is a stable pharmaceutical solution formulation of a GLP-1R antibody fusion protein, comprising a therapeutically effective amount of the GLP-1R antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stable solution formulation is from 5.0 to 8.0. The stable solution formulation of the present invention can be used in the treatment of diabetes, obesity and conditions associated therewith.

The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for trans plantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.

The invention relates to medicine and chemical and pharmaceutical industry, in particular, to methods for producing a complex of biologically active substances exhibiting hypoglycaemic activity of plant material. A method for producing a complex of biologically active substances exhibiting hypoglycaemic activity comprises extracting bean herb with alcohol followed by concentrating and/or drying the extract, wherein the extraction is carried out with 96% alcohol resulting in a first extract and a bean herb residue, wherein the first extract is concentrated resulting in a first solid extract or it is concentrated and dried resulting in a first dry extract and the bean herb residue is extracted with 70% alcohol resulting in a second extract at least a portion of which being concentrated resulting in a second solid extract or being concentrated and dried resulting in a second dry extract.

The disclosure provides compounds of Formula (I-A) and (I-B) and the pharmaceutically acceptable salts thereof. The variables, R, R.sup.2, R.sup.3, X.sup.1, X.sup.2, X.sup.3, Y.sup.1, Y, and Z are defined herein. Certain compounds of Formula (I-A) and (I-B) act as selective mitochondrial protonophore uncouplers that do not affect plasma membrane potential. These compounds are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH), Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, the compounds are useful for increasing lifespan. Compounds and salts of Formulae (I-A) and (I-B) are also useful for regulating glucose homeostasis or insulin action in a patient. ##STR00001##

Disclosed are compositions and methods for inducing sustained diabetes remission by single administration of FGF1 to the brain. The composition and methods described herein result in basal glucose clearance by using a dosage of FGF1 that is lower than that needed for systemic efficacy and is devoid of the risk of hypoglycemia and changes in body weight, food intake, hepatic glucose production, insulin secretion or insulin sensitivity.

This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

Novel peptides and their uses are provided. In particular, the peptides are useful for increasing glucose uptake or decreasing hepatic glucose production. The peptides are also useful for regulating glucose levels and/or treating diabetes in a subject.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.